During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
CASE SUMMARY
Three years later
DISCUSSION QUESTIONS
LOUAY HANNA, MD: What about selinexor [Xpovio], bortezomib, and dexamethasone [XVd]? We have strong data in the second line, especially if this patient needs [therapy for] high disease burden.1 You want some completely new mechanism of action. I would think XVd might be a better option. But if this patient had soft relapse on 10 mg of lenalidomide, I wouldn’t say they’re completely resistant to IMiD [immunomodulatory imide drug]. So maybe they could receive carfilzomib [Kyprolis] and pomalidomide [Pomalyst] or bortezomib plus dexamethasone, or lenalidomide, bortezomib, and dexamethasone.
JONATHAN L. KAUFMAN, MD: I’m glad you mentioned bortezomib, selinexor, and dexamethasone…. [The BOSTON trial (NCT03110562)] is exactly the one that you mentioned. There are a lot of phase 3 data in this situation but this is one of the trials that was not talked about.
MAURIZIO BENDANDI, MD: Why does this patient have heavy tumor burden on relapse? I would expect the disease not to be explosive, since he was on DRd…. I don’t know that I would engage in selinexor in a 79-year-old patient who most likely is going to have GI [gastrointestinal] toxicity. I understand they’re 2 different mechanisms of action, [but] selinexor is not an easy medication.
SHEBLI ATRASH, MD: Selinexor dosed at 160 mg a week, meaning 80 mg twice a week, got the reputation of nausea, vomiting, and GI problems [in the STORM trial (NCT02336815)].2 I can tell you [that with] a dose of 40 mg a week or 60 mg a week, you still get great efficacy with very minor GI toxicity.
KAUFMAN: I say this all the time—we learn so much more about a drug after the drug is approved. [The BOSTON] study used selinexor weekly, continuous dosing every week at 100 mg. But exactly what Dr Atrash said, we don’t use 100 mg every week; we use 40 mg to 60 mg for 3 out of 4 weeks. We don’t have randomized data [comparing dose levels], but I’m able to maintain efficacy. This study in this similar patient population [showed benefit of] bortezomib, selinexor, and dexamethasone vs bortezomib and dexamethasone [Vd].1
BENDANDI: But how many patients in this study were [aged] 79? Even reduced-dose selinexor, at [the age of] 79, is not an easy medication in my opinion.
KAUFMAN: Let’s say the patient is aged 75, or they started when they’re 70 and now they’re 75. Or a patient was transplanted and was progressing was on the PERSEUS [NCT03710603] regimen 2 or 3 years later on daratumumab/lenalidomide. There would be a variety of agents that could come in.
BENDANDI: I started using selinexor [soon] after it was approved in the second line with bortezomib, but for [a patient aged] 79, it’s not easy.
KAUFMAN: No, we agree. [In terms of the outcomes with BOSTON], there was benefit in the primary [end point] with a statistically significant, clinically significant 4-month improvement in progression-free survival [(PFS) 13.93 months median with XVd vs 9.46 with Vd], but I don‘t think these are the key data.1
There was a somewhat higher [objective] response rate: 76% [with XVd] vs 62% with Vd. The median duration of response is 20 months vs 13 months, respectively. In 76% of patients [treated with XVd], you‘re looking at a year and a half of benefit. [Although] we don’t have the [subgroup data] for the older patient population [of 75 or older], for those patients who hadn‘t had a prior proteasome inhibitor [PI], there was a 30-month [median PFS with selinexor] vs 10 months [without it]. It looks like there’s something there because that’s the key with these patients who we’re seeing now with the DRd. These are very small numbers, less than 50 patients in each arm [with no prior PI], but that looks good.
If you’ve ever used selinexor, there’s hematologic toxicity and non-hematologic toxicity. [I believe] 100 mg is not the right dose once a week. I don’t think 80 mg is the right dose; I think it’s somewhere between 40 mg and 60 mg, and I typically give it 3 out of 4 weeks. That’s been my approach for how I use this medication.
Patient selection is critical here. For a frail 79-year-old, maybe [they should not be selected, but it could be used in] a fit younger patient who is refractory to daratumumab and lenalidomide, and maybe a patient [who] hasn’t seen a PI for whatever reason. This patient hasn’t seen a PI…and I agree they need a PI.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More